Heron Therapeutics (NASDAQ:HRTX) Rating Reiterated by JMP Securities

JMP Securities reaffirmed their outperform rating on shares of Heron Therapeutics (NASDAQ:HRTX) in a research report sent to investors on Tuesday, The Fly reports. They currently have a $38.00 price target on the biotechnology company’s stock, up from their prior price target of $33.00.

A number of other brokerages have also recently weighed in on HRTX. Cowen reiterated a buy rating and set a $40.00 price target on shares of Heron Therapeutics in a research report on Tuesday. BidaskClub cut shares of Heron Therapeutics from a buy rating to a hold rating in a research report on Thursday, September 26th. Stifel Nicolaus reiterated a buy rating and set a $38.00 price target on shares of Heron Therapeutics in a research report on Monday, August 5th. ValuEngine upgraded shares of Heron Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 1st. Finally, Evercore ISI reiterated a buy rating and set a $75.00 price target on shares of Heron Therapeutics in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of Buy and an average price target of $48.50.

HRTX stock traded down $1.94 during trading on Tuesday, reaching $17.42. 6,534,755 shares of the stock were exchanged, compared to its average volume of 998,477. The company has a current ratio of 4.01, a quick ratio of 3.70 and a debt-to-equity ratio of 0.04. The business has a 50 day moving average price of $18.72 and a 200-day moving average price of $19.54. Heron Therapeutics has a 1 year low of $15.68 and a 1 year high of $32.45. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -7.14 and a beta of 1.42.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. Heron Therapeutics had a negative net margin of 172.07% and a negative return on equity of 56.89%. The company had revenue of $36.66 million for the quarter, compared to the consensus estimate of $31.04 million. On average, research analysts anticipate that Heron Therapeutics will post -2.73 EPS for the current year.

In other Heron Therapeutics news, EVP John Poyhonen acquired 5,143 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was purchased at an average price of $17.50 per share, for a total transaction of $90,002.50. Following the completion of the acquisition, the executive vice president now owns 18,143 shares of the company’s stock, valued at approximately $317,502.50. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Barry D. Quart acquired 4,571 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was acquired at an average price of $17.50 per share, with a total value of $79,992.50. Following the acquisition, the chief executive officer now directly owns 90,081 shares of the company’s stock, valued at approximately $1,576,417.50. The disclosure for this purchase can be found here. Insiders own 12.56% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Chartwell Investment Partners LLC grew its holdings in Heron Therapeutics by 1.1% during the 2nd quarter. Chartwell Investment Partners LLC now owns 100,171 shares of the biotechnology company’s stock worth $1,862,000 after acquiring an additional 1,129 shares in the last quarter. Royal Bank of Canada grew its holdings in Heron Therapeutics by 154.6% during the 2nd quarter. Royal Bank of Canada now owns 31,767 shares of the biotechnology company’s stock worth $591,000 after acquiring an additional 19,290 shares in the last quarter. Voloridge Investment Management LLC acquired a new position in Heron Therapeutics during the 2nd quarter worth approximately $1,302,000. Nuveen Asset Management LLC acquired a new position in Heron Therapeutics during the 2nd quarter worth approximately $7,169,000. Finally, UBS Asset Management Americas Inc. grew its holdings in Heron Therapeutics by 14.4% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 65,859 shares of the biotechnology company’s stock worth $1,224,000 after acquiring an additional 8,280 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: What are different types of coverage ratios?

The Fly

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.